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Important progress has been made during the last decade
in terms of standardized antibiotic usage studies that allow
comparisons between countries. The driving force behind
this development has been the European Surveillance of
Antimicrobial Consumption (ESAC) project [1, 2]. One
of the most striking observations remains the marked
international differences in the volume and pattern of out-
patient antibiotic use. In the current issue of INFECTION,
Nitzan and colleagues [3] report detailed data on outpatient
antibiotic use in a country participating in ESAC (Israel) that
were collected between 2003 and 2005.
The researchers analyzed prescription data from the
largest Health Maintenance Organization in Israel, which
covers slightly more than half of the total population. They
found a modest, yet significant reduction in outpatient
antibiotic use over the study period. This finding should,
however, be interpreted with caution. As mentioned by the
authors [3], analyzing trends over just a 3-year period is
problematic. Most importantly, recent ESAC data for
Israel, which presumably come from the same data source,
do not confirm the positive trend reported by the authors.
The ESAC data for 2006 show an increase in antibiotic use to
22.2 defined daily doses (DDD)/1,000 inhabitants per day
[4]. It would thus have been interesting to have seen more
recent data included in this study. Moreover, this recently
observed opposite trend demonstrates the dangers of over-
interpreting temporary trends over short study periods,
which may just be the result of random or seasonal variation
in the incidence of respiratory tract infections and influenza.
Clearly, before drawing any firm conclusions, researchers are
well advised to generate more extended time-series and to
analyze these with accurate statistical analytical methods
that account for the interdependence of data points [5].
Nitzan and colleagues [3] also found differences in the
quantity and quality of antibiotic prescribing between dif-
ferent regions within Israel. This observation confirms
observations from several other countries [6, 7]. As is the
case for variations in antibiotic use between countries, the
reasons for variations between regions are only incompletely
understood and difficult to pin down, although they certainly
involve socio-cultural and demographic factors (including
physician density) more than differences in disease incidence
and presentation [8, 9]. Interestingly, the researchers from
Israel explored the potential association between demo-
graphic data and regional variation in antibiotic use. They
found that the age distribution within a region influences
antibiotic consumption patterns, which is not surprising since
antibiotic prescribing for children is particularly high.
Moreover, after performing a multivariate analysis, Nitzan
and colleagues [3] found a significant association between
antibiotic consumption and the prevalence of diabetes mel-
litus in certain regions. Although this finding may be plau-
sible considering the many chronic health problems of
diabetic patients, it should be interpreted with caution, since
the use of individual patient data may have given different
results. As stated by the authors, the true reasons for the
interregional variation in Israel remain elusive.
How should clinicians and policy-makers interpret
these findings from Israel? The total volume of outpatient
antibiotic use in Israel is similar to that of the USA,
Australia, Spain, and Italy and relatively high compared
to some Northern or Central European countries [1, 2, 10].
Although Israel has a high density of academic centers
with renowned infectious disease services, this does not
seem to protect the country against antibiotic misuse by
general practitioners and pediatricians, who may be more
influenced by patient expectations and beliefs, knowledge
gaps, diagnostic uncertainty, and marketing pressure.
Some experts even argue that in many countries such as
Israel, tight links between academic opinion leaders and
the pharmaceutical industry may have accelerated the
diffusion and overuse of new broad-spectrum antibiotics
both in the inpatient and outpatient settings.
Antibiotic use is associated with the selection and cre-
ation of antibiotic resistant bacteria and reducing antibiotic
use can positively influence antibiotic resistance [11, 12].
This is nicely illustrated by two recent studies from Israel.
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In the first study, Dagan and colleagues [13] showed that the
lower antibiotic use in Jewish children during the summer
months is associated with lower rates of antibiotic resistance
in Streptococcus pneumoniae during these months. In a
second study, Gottesman and colleagues [14] found that a
widespread decrease in fluoroquinolone use after introduc-
tion of a short-term national restriction policy in 2001 led to
an increase in susceptibility to fluoroquinolones of Esche-
richia coli in urinary isolates, which reversed immediately
when fluoroquinolone consumption increased again.
National campaigns in Belgium and France have
recently shown that it is possible to reduce outpatient
antibiotic use by extended mass media campaigns [6, 15,
16]. Similar campaigns to reduce unnecessary antibiotic
use have been conducted in Israel by another HMO [17],
different from that described in the article by Nitzan et al.
[3]. A recent paper suggests that the 2006 campaign on
antibiotic prescribing has had some impact, at least in the
HMO organizing the campaign. In Europe, evidence on
the best ways to promote judicious outpatient antibiotic
use has been gathered in the context of the EU-funded
CHAMP project (Changing Behavior of Health Care Pro-
fessionals and the General Public Towards a More Prudent
Use of Anti-Microbial Agents), whose aim is to develop
recommendations for policy-makers on how to improve
outpatient antibiotic use [18].
Studies such as the one by Nitzan and colleagues [3]
are important in order to gain further insight into the
reasons for variations in antibiotic use within or between
countries. They should, however, be followed by well-
designed interventions to reduce unnecessary antibiotic
use adapted to the specific country setting. Clearly, there
is still room for improvement in Israel (as in many other
countries). Although the optimal level and pattern of
outpatient antibiotic use are not clear, it is probably safe
to assume that it can be reduced to the level of several
European countries that are below 15 DDD/1,000 inhab-
itants per day, without harming patient safety and
increasing the risk of major adverse outcomes.
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